Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: What is the evidence for its benefit?

Clinical Therapeutics

Volumn 26, Issue 12, 2004, Pages 2130-2137

  Geskey, Joseph M ^a   Ceneviva, Gary D ^a   Brummel, Gretchen L ^a   Graff, Gavin R ^a   Javier, Maria Cristina ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Immunoprophylaxis; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

AGE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; COST CONTROL; EVIDENCE BASED MEDICINE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INCIDENCE; INFANT; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; OUTPATIENT; PUBLICATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SAMPLE SIZE; SATISFACTION; STANDARDIZATION; SYSTEMATIC REVIEW; VIRUS INFECTION;

EID: 14844363634     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.12.005     Document Type: Article

References (38)

1. Division of Health Promotion and Disease Prevention, Division of International Health, and Institute of Medicine The prospects for immunizing against respiratory syncytial virus New Vaccine Development: Establishing Priorities. Volume II: Diseases of Importance in Developing Countries 1986 National Academies Press St. Louis, Mo 299 307
2. Leader S, and Kohlhase K Respiratory syncytial virus--coded pediatric hospitalizations, 1997 to 1999 Pediatr Infect Dis J. 21 2002 629 632
3. Thompson WW, Shak DK, and Weintraub E Mortality associated with influenza and respiratory syncytial virus in the United States JAMA 289 2003 179 186
4. Shay DK, Holman RC, and Roosevelt GE Bronchiolitis-associated mortality and estimates of respiratory syncytial virus--associated deaths among US children, 1979-1997 J Infect Dis. 183 2001 16 22
5. Holman RC, Shak DK, and Curns AT Risk factors for bronchiolitis- associated deaths among infants in the United States Pediatr Infect Dis J. 22 2003 483 490
6. Groothuis JR, Gutierrez KM, and Lauer BA Respiratory syncytial virus infection in children with bronchopulmonary dysplasia Pediatrics 82 1998 199 203
7. Hall CB, Powell KR, and MacDonald NE Respiratory syncytial viral infection in children with compromised immune function N Engl J Med. 315 1986 77 81
8. MacDonald NE, Hall CB, and Suffin SC Respiratory syncytial viral infection in infants with congenital heart disease N Engl J Med. 307 1982 397 400
9. Howard TS, Hoffman LH, Stang PE, and Simoes EA Respiratory syncytial virus pneumonia in the hospital setting: Length of stay, charges, and mortality J Pediatr. 137 2000 227 232
10. Miedema CJ, Kors AW, Tjon A, Ten WE, and Kimpen JL Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in the Netherlands Pediatr Infect Dis J. 20 2001 160 163
11. RespiGam [package insert] 1996 MedImmune, Inc Washington, DC
12. Palivizumab [package insert] 1998 MedImmune, Inc Gaithersburg, Md
13. Groothuis JR, Simoes EA, Levin MJ Respiratory Syncytial Virus Immune Globulin Study Group Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children N Engl J Med. 329 1993 1524 1530
14. The PREVENT Study Group Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis Pediatrics 99 1997 93 99
15. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalizations from respiratory syncytial virus infection in high-risk infants Pediatrics 102 1998 531 537
16. 2003 Drug Topics Red Book 2003 Thomson PDR Gaithersburg, Md
17. Joffe S, Ray GT, and Escobar GJ Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants Pediatrics 104 1999 419 427
18. Vogel AM, Lennon DR, and Broadbent R Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants J Paediatr Child Health 38 2002 550 554
19. Shireman TI, and Braman KS Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas Medicaid's high-risk children Arch Pediatr Adolesc Med 156 2002 1251 1255
20. Schrand LM, Elliott JM, and Ross MB A cost-benefit analysis of RSV prophylaxis in high-risk infants Ann Pharmacother 35 2001 1186 1193
21. Kamal-Bahl S, Doshi J, and Campbell J Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: A systematic review Arch Pediatr Adolesc Med 156 2002 1034 1041
22. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections Pediatrics 112 2003 1442 1446
23. American Academy of Pediatrics, and American College of Obstetricians and Gynecologists Guidelines for Perinatal Care 5th ed. 2002 American Academy of Pediatrics and American College of Obstetricians and Gynecologists Montvale, NJ
24. Robbins JM, Tilford JM, and Gillaspy SR Parental emotional and time costs predict compliance with respiratory syncytial virus prophylaxis Ambul Pediatr. 2 2002 444 448
25. Hashmi NA, Cosgrove JF, and MacMahon P Prophylaxis in RSV infection (palivizumab)--Is it worthwhile? Ir Med J 93 2000 284
26. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J IRIS Study Group Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants Pediatr Infect Dis J 22 2003 823 827
27. Coffman C, Peck J, and Rasmussen CS Developing a Synagis clinic for respiratory syncytial virus prophylaxis MCN Am J Matern Child Nurs 26 2001 246 252
28. Singleton RS, Dooley L, and Bruden D Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants Pediatr Infect Dis J 22 2003 540 545
29. Parnes C, Guillermin J, Habersang R Palivizumab Outcomes Registry Study Group Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: Results from the Palivizumab Outcomes Registry Pediatr Pulmonol 35 2003 484 489
30. Paul DA, Leef KH, and Chidekel A Home delivery of palivizumab: Outcomes and compliance in regional preterm infants Del Med J 74 2002 11 15
31. Carbonell-Estrany X Palivizumab outcomes registry data from Spain: Infecci n Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group Pediatr Infect Dis J 22 Suppl 2 2003 S55 S57
32. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV Pediatrics 102 1998 1211 1216
33. Muldoon JH Structure and performance of different DRG classification systems for neonatal medicine Pediatrics 103 Suppl E 1999 302 318
34. Respiratory syncytial virus activity--United States, 2000-01 season MMWR Morb Mortal Wkly Rep 51 2002 26 28
35. Johnson S, Oliver C, and Prince GA Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus J Infect Dis 176 1997 1215 1224
36. Subramanian KN, Weisman LE, Rhodes T MEDI-493 Study Group Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia Pediatr Infect Dis J 17 1998 110 115
37. Langkamp DL, and Illvin SM Factors predicting compliance with palivizumab in high-risk infants Am J Perinatol 18 2001 345 352
38. Feltes TF, Cabalka A, Meissner C Cardiac Synagis Study Group Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease J Pediatr 143 2003 532 540